Ioxilan

Last updated
Ioxilan
Ioxilan structure.png
Clinical data
Trade names Oxilan
AHFS/Drugs.com FDA Professional Drug Information
Routes of
administration 		intravenously
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability N/A
Protein binding negligible
Metabolism none
Elimination half-life 2 hours
Excretion Mostly renal
Identifiers
  • 1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C18H24I3N3O8
Molar mass 791.116 g·mol−1
3D model (JSmol)
  • O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C
  • InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) Yes check.svgY
  • Key:UUMLTINZBQPNGF-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Ioxilan is a diagnostic contrast agent. [1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but was discontinued in 2017. [2]

Mechanism of action

Ioxilan is an iodinated contrast agent. [2]

References

  1. ↑ Cheng KT (December 2007). "Ioxilan carbonate particles". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID   20641969.
  2. 1 2 Oxilan FDA Professional Drug Information . Accessed 2021-04-07.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.